Grizzly Research is short GeneDx (WGS), saying insiders attest that the company is “actively committing widespread fraud.” In a recently ...

In 2022, before changing its name from Sema4 to GeneDx, the company had a dispute with UnitedHealthcare, which resulted in a ...

EST GeneDx (WGS) down 3% after Grizzly Research publishes short report, alleging fraudMaximize Your Portfolio with Data Driven ...

Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

These contributions, added to GeneDx’s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance ...

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) and adjusted gross margin of at least 64% (previous guidance was at least ...

These contributions, added to GeneDx’s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance ...

These contributions, added to GeneDx’s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance, and ...